AJP - Heart AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 297: H627-H636, 2009. First published June 5, 2009; doi:10.1152/ajpheart.00294.2009
0363-6135/09 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/2/H627    most recent
00294.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Gupta, S.
Right arrow Articles by Sen, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, S.
Right arrow Articles by Sen, S.

Silencing the myotrophin gene by RNA interference leads to the regression of cardiac hypertrophy

Sudhiranjan Gupta, Ratan Maitra, Dave Young, Anasuya Gupta, and Subha Sen

Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio

Submitted 24 March 2009 ; accepted in final form 3 June 2009

Myotrophin-induced activation of NF-{kappa}B has been shown to be associated with cardiac hypertrophy (CH) that progresses to heart failure (HF). In the present study, we examined the cause-and-effect relationship between myotrophin and NF-{kappa}B activation using small hairpin RNA (shRNA) against myotrophin both in vitro (using neonatal rat myocytes) and in vivo [using myotrophin transgenic (Myo-Tg) mice, which overexpress myotrophin in the heart, develop CH, and gradually progress to HF]. Among several lentiviral vectors expressing myotrophin shRNAs, L-sh-109 showed the best silencing effect at both the mRNA (155.3 ± 5.9 vs. 32.5 ± 5.5, P < 0.001) and protein levels associated with a significant reduction of atrial natriuretic factor (ANF) and NF-{kappa}B. In vivo, when L-sh-109 was delivered directly into the hearts of 10-wk-old Myo-Tg mice, we observed a significant regression of cardiac mass (8.0 vs. 5.7 mg/g, P < 0.001) and myotrophin gene expression (54.5% over untreated Myo-Tg mice, P < 0.001) associated with a reduction in ANF and NF-{kappa}B signaling components. Our data suggest that using RNA interference to silence the myotrophin gene prevents NF-{kappa}B activation, associated with an attenuation of CH. This strategy could be an excellent therapeutic means for the treatment of CH and HF.

nuclear factor-{kappa}B; heart failure



Address for reprint requests and other correspondence: S. Sen, Dept. of Molecular Cardiology (NB 50), Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195 (e-mail: sens{at}ccf.org)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2009 by the American Physiological Society.